Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin (SOTA-EMPA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03351478
Recruitment Status : Completed
First Posted : November 22, 2017
Results First Posted : May 11, 2021
Last Update Posted : May 11, 2021
Sponsor:
Collaborator:
Sanofi
Information provided by (Responsible Party):
Lexicon Pharmaceuticals

Brief Summary:
The purpose of the study is to demonstrate the superiority of sotagliflozin versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control on a DPP4(i) with or without metformin.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Drug: Sotagliflozin Drug: Empagliflozin Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 770 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Participants With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Actual Study Start Date : November 27, 2017
Actual Primary Completion Date : May 16, 2019
Actual Study Completion Date : May 16, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Sotagliflozin 400 mg
Following a 2-week run-in period, sotagliflozin 400 mg (milligrams) administered as two 200 mg tablets and one placebo capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day for up to 26 weeks.
Drug: Sotagliflozin
Sotagliflozin 400 mg was administered as two tablets, once daily before the first meal of the day.
Other Name: SAR439954

Drug: Placebo
Placebo was administered as one capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day.

Active Comparator: Empagliflozin 25 mg
Following a 2-week run-in period, placebo matching sotagliflozin administered as two tablets (identical to sotagliflozin in appearance) and one capsule of empagliflozin 25 mg, once daily before the first meal of the day for up to 26 weeks.
Drug: Empagliflozin
Empagliflozin 25 mg capsule was administered, once daily before the first meal of the day.

Drug: Placebo
Placebo was administered as two tablets (identical to sotagliflozin in appearance), once daily before the first meal of the day.

Placebo Comparator: Placebo
Following a 2-week run-in period, placebo was given as two placebo tablets (identical to sotagliflozin) and one placebo capsule (identical to empagliflozin) once daily before the first meal of the day for up to 26 weeks.
Drug: Placebo
Placebo was administered as two tablets (identical to sotagliflozin in appearance), once daily before the first meal of the day.




Primary Outcome Measures :
  1. Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26 [ Time Frame: Baseline, Week 26 ]
    An analysis of covariance (ANCOVA) model was used for the analysis.


Secondary Outcome Measures :
  1. Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 12 in Participants With Baseline SBP ≥ 130 mmHg [ Time Frame: Baseline, Week 12 ]
    An ANCOVA model was used for the analysis.

  2. Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Mixed Meal at Week 26 [ Time Frame: Baseline, Week 26 ]
    An ANCOVA model was used for the analysis.

  3. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 [ Time Frame: Baseline, Week 26 ]
    An ANCOVA model was used for the analysis.

  4. Change From Baseline in Body Weight at Week 26 [ Time Frame: Baseline, Week 26 ]
    An ANCOVA model was used for the analysis.

  5. Change From Baseline in Sitting SBP at Week 12 for All Participants [ Time Frame: Baseline, Week 12 ]
    An ANCOVA model was used for the analysis.

  6. Percentage of Participants With HbA1c <6.5% at Week 26 [ Time Frame: Week 26 ]
  7. Percentage of Participants With HbA1c <7.0% at Week 26 [ Time Frame: Week 26 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria :

  • Participants with Type 2 Diabetes on Dipeptidyl peptidase-4 inhibitors(DPP4(i)) with or without metformin at a stable dose for at least 12 weeks prior to Screening Visit. Metformin dose will be ≥1500 mg per day (or maximum tolerated dose [documented]). DPP4(i) dose must be the appropriate dose as per local label.
  • Signed written informed consent.

Exclusion criteria:

  • Body mass index (BMI) ≤20 kg/m^2 or >45 kg/m^2 at Screening.
  • Use of any antidiabetic drug other than DPP4 inhibitors and metformin within 12 weeks preceding the Screening Visit.
  • Participants who have previously participated in any clinical trial of sotagliflozin/LX4211.
  • Use of a selective sodium-glucose co-transporter type 2 (SGLT2) inhibitor (e.g., canagliflozin, dapagliflozin, or empagliflozin) within 3 months prior to the screening visit.
  • Participants with severe anemia, severe cardiovascular disease (including congestive heart failure New York Heart Association IV), respiratory, hepatic, neurological, psychiatric, or active malignant tumor or other major systemic disease or participants with a short life expectancy that, according to Investigator, will preclude their safe participation in this study, or will make the implementation of the protocol or interpretation of the study results difficult.
  • Current diagnosis of chronic hepatitis and/or other clinically active liver disease requiring treatment.
  • Participants with contraindication to empagliflozin as per local labelling.
  • Participants with contraindication to metformin as per local labelling.
  • Hemoglobin A1c <7.0% or >11.0% at Screening (central laboratory).
  • Fasting plasma glucose >270 mg/dL (>15.0 mmol/L) measured by the central laboratory at Screening (Visit 1), and confirmed by a repeat test (>270 mg/dL [>15.0 mmol/L]) before Randomization.
  • Previous use of any type of insulin for >1 month (except for treatment of gestational diabetes).
  • Pregnant (confirmed by serum pregnancy test at Screening) or breast-feeding women.
  • Women of childbearing potential not willing to use highly effective method(s) of birth control during the study treatment period and follow-up period, or who are unwilling or unable to be tested for pregnancy during the study.
  • Mean of 3 separate blood pressure (BP) measurements >180 mmHg (systolic blood pressure [SBP]) or >100 mmHg (diastolic blood pressure [DBP]).
  • History of the hypertensive crisis resulting in emergency medical care within 12 weeks prior to Screening Visit.
  • Lower extremity complications (such as skin ulcers, infection, osteomyelitis, and gangrene) identified during the Screening period, and still requiring treatment at Randomization.
  • Laboratory findings with the central laboratory tests at Visit 1:
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of the normal laboratory range (ULN);
  • Total bilirubin >1.5 times the ULN (except in case of Gilbert's syndrome);
  • Neutrophils <1 500/mm^3 (or according to ethnic group) and/or platelets <100 000/mm^3;
  • Amylase and/or lipase >3 times the ULN;
  • Participants with renal impairment as defined by the estimated glomerular filtration rate (eGFR) criterion that precludes initiation of empagliflozin as per the approved local label (eg, <45 mL/min/1.73 m^2 in US; <60 mL/min/1.73 m^2 in EU).
  • Secondary hypertension of any etiology (eg, renovascular disease, pheochromocytoma, Cushing's syndrome).
  • If the participant is on hypertensive medications, the antihypertensive has been changed in the 8 weeks prior to Screening (new drug or new dose).

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03351478


Locations
Show Show 160 study locations
Sponsors and Collaborators
Lexicon Pharmaceuticals
Sanofi
Investigators
Layout table for investigator information
Study Director: Suman Wason Lexicon Pharmaceuticals, Inc.
  Study Documents (Full-Text)

Documents provided by Lexicon Pharmaceuticals:
Study Protocol  [PDF] April 12, 2018
Statistical Analysis Plan  [PDF] November 15, 2019

Layout table for additonal information
Responsible Party: Lexicon Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03351478    
Other Study ID Numbers: EFC14867
2016-001803-22 ( EudraCT Number )
U1111-1190-7607 ( Other Identifier: UTN )
First Posted: November 22, 2017    Key Record Dates
Results First Posted: May 11, 2021
Last Update Posted: May 11, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Empagliflozin
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
Sodium-Glucose Transporter 2 Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs